ArticleJournal of gastrointestinal oncology2025
Case report of carcinoid syndrome with multi-organ involvement.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carcinoid syndrome (CS) is a rare complication of neuroendocrine tumors (NETs). Characterized by cutaneous flushing, diarrhea, abdominal pain, and long-term risk for valvular heart disease, these components occur in a fraction of patients with advanced disease. Early recognition through history taking, physical and laboratory examination, and clinical imaging is paramount to successful management. Case Description: We report a case of CS in a 21-year-old male patient found to have a metastatic gastrointestinal, well differentiated (Ki67 <3%) NET. The patient presented with cutaneous flushing, diarrhea, abdominal pain, dyspnea, ascites, and peripheral edema. On imaging, he was found to have a massive left pleural effusion, innumerable enhancing hepatic lesions, mesenteric lymphadenopathy, and large-volume ascites. Cardiac imaging further showed severe tricuspid regurgitation and right heart failure. Biopsy of the enhancing hepatic lesions showed a grade 1 NET of gastrointestinal origin. Urine testing revealed markedly high serotonin metabolites. The patient was started on somatostatin analogues, which resulted in improved control of diarrhea and flushing. Thoracoscopic surgery improved pleural effusion accumulation, and recurrent abdominal ascites was treated with paracentesis when necessary. He was also referred to cardiothoracic surgery tricuspid valve replacement surgery. Conclusions: Our case illustrates the classic characteristics of CS as well as valvular heart disease supported by clinical imaging of the syndrome's involvement of multiple organ systems. These findings are important for physicians to recognize as early recognition of CS can lower the risk of long-term complications of carcinoid heart disease. Additionally, patients with limited access to healthcare may be at risk of later CS presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.